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Abstract  The  use  of  stents  in  the  gastrointestinal  tract  has  been  subjected  to  major  changes.
Initially, the  use  of  stents  was  restricted  to  malignant  strictures  in  patients  with  metastatic
disease. But  thanks  to  reduction  of  the  morbidity  and  mortality  rates,  they  are  now  used  with
curative  intention  and  in  patients  with  benign  diseases  after  careful  selection.  However,  for
patients presenting  with  colon  obstruction  due  to  an  advanced  colon  carcinoma,  the  mortality
and morbidity  are  still  high.  The  purpose  of  this  review  is  to  provide  an  overview  of  indications,
techniques  and  further  developments  of  the  stents  in  the  gastrointestinal  tract  and  to  highlight
the predominant  role  of  multidetector  row  computed  tomography  (MDCT)  in  the  detection  of
potential complications.©  2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.Since  1990,  stents  have  been  used  in  the  gastrointestinal  tract  mirroring  prior  use  for
hepatobiliary  diseases.  Initially,  only  malignant  gastrointestinal  tract  strictures  have  been
treated  with  stent  in  patients  with  metastatic  disease.  But  thanks  to  marked  drop  in  mor-
bidity  and  mortality  rates,  stents  have  been  further  used  for  curative  purpose  and  in  benign
Abbreviations: MDCT, multidetector row computed tomography; SEMS, self-expandable metallic stent.
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to  those  of  conventional  SEMS.  Although  some  of  the  stents94  
astrointestinal  conditions.  More  recently,  substantial
mprovements  have  been  observed  regarding  gastrointesti-
al  tract  stents  in  order  to  improve  technical  and  clinical
uccess  rates  and  to  reduce  morbidity  rates.
The  purpose  of  this  review  is  to  provide  an  overview
f  indications,  techniques  and  further  developments  of
he  stents  in  the  gastrointestinal  tract  and  to  high-
ight  the  predominant  role  of  multidetector  row  com-
uted  tomography  (MDCT)  in  the  detection  of  potential
omplications.
sophagus
ess  than  50%  of  patients  with  esophageal  carcinoma  are
otential  candidates  to  surgical  resection.  By  contrast,  most
f  patients  with  esophageal  carcinoma  have  a  disease  that
s  diagnosed  at  an  advanced  stage,  being  disseminated  or
etastatic.  In  such  patients,  dysphagia  is  the  main  clini-
al  symptom  and  so  that  palliative  treatment  is  required.
alliative  treatment,  however,  can  also  result  in  prolonged
urvival  time  [1].
ndications
alignant strictures
urrently,  self-expandable  metallic  stent  (SEMS)  insertion
s  the  most  common  intervention  for  palliation  of  dyspha-
ia  in  inoperable  patients  with  esophageal  cancer  [2,3].
EMS  is  a  safe  and  effective  treatment  in  dysphagia  pal-
iation  compared  to  other  modalities  [3].  In  the  same
ime,  high-dose  intraluminal  brachytherapy  is  a  suitable
lternative  with  fewer  requirements  for  re-intervention,
dditional  survival  beneﬁts  and  a  better  quality  of  life
3,4].  The  combination  of  stent  insertion  and  brachyther-
py  seems  to  be  a  feasible  and  safe  palliative  option  in
atients  with  inoperable  esophageal  carcinoma  [5]. There
s  still  no  evidence  to  recommend  the  appropriate  timing  of
EMS  insertion  in  combination  with  other  modalities.  Non-
andomized  studies  [6,7]  have  reported  conﬂicting  results
egarding  complication  rate  after  SEMS  insertion  among
atients  who  have  undergone  previous  radiochemother-
py  and  only  two  studies  have  reported  an  increased
ate  of  stent-related  complications  after  SEMS  insertion
n  patients  previously  treated  with  radiochemotherapy
8,9].
The  use  of  esophageal  stents  in  patients  receiving  neoad-
uvant  therapy  before  surgery  have  been  studied  but  is
till  debated  because  the  treatment  of  dysphagia  is  not
lways  sufﬁcient  to  improve  the  nutritional  status  of  the
atients  and  is  associated  with  non-negligible  morbidity
10].  Since  the  1990s,  esophageal  intubation  with  stents
as  gradually  developed  with  high  rates  of  complete  closure
f  tracheo/broncho-esophageal  ﬁstula  and  improvement  in
ymptoms  of  respiratory  tract  and  quality  of  life  [11—13].
n  a  retrospective  analysis,  Chen  et  al.  reported  that  SEMS
ould  also  signiﬁcantly  improve  the  overall  survival  in  such
atients  [14].  Malignant  esophageal  ﬁstula  and  strictures
ue  to  villous  tumors  with  budding  are  the  main  indica-
ion  of  partially  covered  stents  because  migration  rate  is
ow  and  removal  is  generally  not  possible  because  of  tissue
a
t
[B.  Malgras  et  al.
mbedding  [15]. In  case  of  external  esophageal  compres-
ion,  SEMS  can  be  performed  but  it  is  generally  less  effective
han  for  intraluminal  lesions  [16].
enign strictures
fter  preliminary  experience  in  malignant  stenosis,  the  use
f  esophageal  stents  have  been  extended  to  benign  stri-
tures.  Benign  esophageal  strictures  are  generally  caused
y  caustic  ingestion,  esophageal  surgery  and  radiotherapy
17,18].  Stents  have  been  proposed  in  refractory  steno-
is  (i.e.,  that  remain  symptomatic  with  dysphagia)  after
p  to  5  repeated  endoscopic  dilations  [19,20]. Esophageal
tents  are  proposed  especially  for  long  stenosis  (>2  cm)
nd  stenting  is  based  on  the  concept  of  temporary,  pro-
ressive,  sustained,  and  large  diameter  dilation.  In  case
f  benign  esophageal  strictures  stents  are  left  in  place
or  a  given  period  of  time  and  systematically  removed.
nitially,  plastic  stents  were  used  (Polyﬂex®,  Boston  Sci-
ntiﬁc,  Marlborough,  MA,  USA),  then  the  use  of  partially
nd  fully  covered  SEMS  was  favored.  Indeed  stents  have
o  be  removed  between  4  to  16  weeks  after  insertion,
nd  between  4  to  8  weeks  for  fully  or  partially  covered
etallic  stents  in  order  to  avoid  epithelial  hyperplasia
nd  stent  incarceration  [21]. Uncovered  metallic  stents
hould  not  be  used  because  of  high  risk  of  incarceration
22].
Stents  have  also  been  used  for  rupture  or  anastomotic
eak  of  the  esophagus  after  surgery  and  is  now  the  treat-
ent  of  choice  (Fig.  1)  [23—25]. Van  Boeckel  et  al.  reported
 high  clinical  success  rate  for  stent  placement  in  a  series
f  267  patients  [26]. In  their  study,  healing  of  the  perfora-
ion  or  leaking  site  was  obtained  in  85%  of  patients,  with
 mean  time  for  healing  of  7  weeks,  with  no  differences
etween  various  type  of  stents  (plastic,  fully  or  partially
overed  stents)  [26].
echnical considerations
erschuur  et  al.  showed  that  the  Polyﬂex® esophageal  stent
as  the  least  preferable  option  compared  to  Ultraﬂex®
Boston  Scientiﬁc)  or  the  Niti-S® stent  (Taewong  Medical,
eoul,  South  Korea)  [27]. This  is  because  the  Polyﬂex® stent
as  more  technically  demanding  and  associated  with  high
ate  of  stent  migration  [27].
Covered  metallic  stents  result  in  effective  and  rapid
elief  of  dysphagia  with  signiﬁcantly  reduced  requirement
or  repeat  interventions  for  recurrent  dysphagia  compared
o  uncovered  metallic  stents  [28].  Covered  metallic  stents
ay  also  help  maintain  general  patient  condition  and
utritional  status  during  chemotherapy  and  radiotherapy.
ncovered  or  partially  covered  stents  can  lead  to  recur-
ent  dysphagia  secondary  to  epithelial  hyperplasia  [22].  In
ddition,  epithelial  hyperplasia  prevents  from  stent  removal
22].
A  variety  of  antireﬂux  stents  are  available  for  palliating
ysphagia  with  complications  rates  and  quality  of  life  similarppeared  effective  in  reducing  gastroesophageal  reﬂux,  fur-
her  research  is  required  to  conﬁrm  this  favorable  outcome
29—34].
Gastrointestinal  stenting:  Current  status  and  imaging  features  595
Figure 1. A 57-year-old man who developed ﬁstula after Lewis-Santi procedure for T3 adenocarcinoma of the cardia: a: MDCT image in
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tthe axial plane shows ﬁstula track (arrow) between the trachea and
in the esophagus. The stent is correctly placed with satisfactory de
During  the  start  of  radiotherapy,  dysphagia  often
increases  due  to  mucositis  and  esophagitis.  SEMS  can
interfere  with  radiotherapy  dose  planning  and  delivery
scheduling  because  of  metallic  content  [35].  Because  the
main  supporting  structure  of  biodegradable  stents  lacks
metallic  material,  they  do  not  interfere  with  radiotherapy.
Also  the  tumor  may  shrink  with  therapy  so  that  metallic
stent  may  migrate  to  the  stomach  and  may  require  further
procedure  for  removal  [36,37].
Potential  beneﬁts  of  using  biodegradable  stents  include
the  avoidance  of  gastrostomy  or  nasoenteric  feeding  tubes
and  improvement  of  quality  of  life  due  to  possible  oral  nutri-
tion.  The  duration  of  courses  of  radiotherapy  (6—8  weeks)
corresponds  to  the  life  span  of  the  biodegradable  stent  [38].
However,  if  a  biodegradable  stent  migrates  during  neoadju-
vant  therapy,  there  is  no  signiﬁcant  clinical  impact  due  to
its  biodegradable  properties,  and  if  it  has  not  migrated,  it
has  substantially  dissolved  at  the  time  of  surgical  resection
[39].
Biodegradable  stents  have  been  proposed  also  for  benign
refractory  esophageal  strictures  in  a  prospective  study
of  21  patients  with  encouraging  results;  indeed  45%  of
patients  were  dysphagia-free  at  the  end  of  the  study.  These
biodegradable  stents  allow  the  avoidance  of  stent  removal
and  have  a  stable  expansion  force  during  5  weeks  [40].
Since  2001,  self-expanding  plastic  stents  have  been  suc-
cessfully  used  in  esophageal  cancer  in  order  to  reduce  the
risk  of  stent  incarceration  secondary  to  epithelial  hyperpla-
sia.  But  because  of  its  cylindric  shape  and  smooth  covering  it
increases  the  risk  of  stent  migration  compared  to  SEMS  (29,
3  and  12%,  respectively  for  plastic,  partially  or  fully  covered
stents)  [27,41].  Also,  plastic  stent  delivery  system  is  wider
and  stiffer  than  SEMS  delivery  system,  often  requiring  a  dila-
tion  before  stent  deployment  leading  to  high  complication
rates  (perforation,  hemorrhage;  9%  versus  3%,  respectively
for  plastic  and  metallic  stents)  [15,41].  They  exert  a  higher
radial  force  than  their  metallic  counterparts,  which  can
lead  to  patient  discomfort,  early  migration,  ulceration,  and
rarely  ﬁstulization  [42].Results
Stent  placement  provides  rapid  and  effective  palliation  of
dysphagia,  but  late  recurrence  of  dysphagia  leads  to  future
7
r
o
d esophagus; b: MDCT image in the axial plane shows metallic stent
ent (arrow).
omplications  that  require  further  endoscopic  treatments
43,44].  Mariette  et  al.  reported  that  SEMS,  as  a  bridge  to
urgery,  has  a  negative  impact  on  outcome  in  patients  with
sophageal  carcinoma,  resulting  in  less  R0  resections,  ear-
ier  recurrences,  a  decreased  3-year  overall  survival,  and  an
ncreased  3-year  locoregional  recurrence  rate  [45].
The  technical  success  rate  of  covered  stent  in  thoracic
nd  abdominal  esophagus  is  >95%.  The  mortality  rate  ranges
etween  0.5  and  2%.
Stents  in  cervical  esophagus  have  usually  been  associ-
ted  with  high  risks  of  perforation,  inhalation,  proximal
tent  migration,  and  poor  tolerance.  However,  Verschuur
t  al.  found  similar  morbidity  and  recurrent  dysphagia  in
atients  with  cervical  and  thoracic/abdominal  esophageal
tents  [46].  Speciﬁc  stents  have  been  designed  for  the
ervical  esophagus,  for  example  the  ‘‘Ultraﬂex’’  (Boston
cientiﬁc)  with  a  low  radial  expansion  force  [47], with  a
mall  proximal  collar  (5  mm)  to  reduce  gastroesophageal
eﬂux  [48], or  with  a proximal  delivery  system  in  order  to
ecure  correct  positioning  of  the  stent  (MITech  Co,  Pyontack,
outh  Korea)  [49]. Only  a few  rare  cases  of  tracheal  compres-
ion  due  to  esophageal  stent  have  been  reported  [50].  It  has
een  suggested  that  high  radial  force  and  anatomic  loca-
ion  of  the  stent  above  the  carina  are  favoring  factors  for
racheal  compression.
The  use  of  plastic  stents  (Polyﬂex®) for  benign  stenosis
ave  also  been  reported  in  many  studies  with  more  than  160
atients  [19]. The  technical  success  rate  was  about  95%,
ither  for  insertion  and  removal.
omplications
arly  morbidity  rate  of  esophageal  stent  placement  is  about
0%  and  may  be  due  to  technical  problems  in  5.3%  of
ases  (misplacement  0.3%,  expansion/deployment  failure  in
.9/0.8%,  stent  migration  in  0.3%)  or  related  to  patients
n  14.6%  of  cases  (pain  12%,  perforation  0.6%,  hemor-
hage  0.6%,  mortality  1.4%).  Late  morbidity  can  also  be
ue  to  technical  problems  (stent  occlusion  secondary  to
issue  in-  and/or  overgrowth  in  11.3%,  stent  migration  in
%)  or  related  to  patients  (gastroesophageal  reﬂux  in  3.7%,
ecurrent  dysphagia  in  8.2%,  esophageal  ﬁstula  in  2.8%,  hem-
rrhage  in  3.9%,  esophageal  perforation  in  0.8%  and  thirty
ay  mortality  in  7.4%)  [51,52]. Esophageal  stent  migration  is
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ore  common  when  stents  are  placed  near  the  gastroesoph-
geal  junction  [53].  The  actual  mechanism  of  hemorrhage
fter  placement  of  esophageal  stent  is  controversial  (pres-
ure  necrosis  of  the  tumor  and  of  the  esophageal  wall  is
ne  of  these).  Some  authors  found  that  bleeding  occurred
ore  frequently  in  patients  whose  stents  extended  to  or
bove  the  level  of  the  aortic  arch,  because  at  this  level
he  left  subclavian  artery  and  the  aortic  arch  have  close
elationships  with  the  posterior  wall  of  the  esophagus  [54].
n  case  of  dysphagia  and  trachea-esophageal  ﬁstula,  the
echnical  success  of  stenting  ranges  between  70  to  100%
46].  Epithelial  hyperplasia  is  very  low  with  plastic  stents,
acilitating  its  removal,  but  high  rates  of  migration  have
een  reported  (between  47  and  64%)  especially  for  proximal
r  distal  stent  location  and  peptic  stenosis  [42,55].  Some
uthors  reported  a  low  migration  rate  after  slight  oversizing
f  stent  diameter  [56].  Others  authors  proposed  a  proximal
xation  of  the  stent  on  the  esophageal  mucosa  by  a  clip
o  prevent  stent  migration  [57].  Delayed  migration  could
e,  at  least  in  some  cases,  the  inevitable  consequence  of
he  dilating  efﬁcacy  of  the  plastic  stents  [58]. Dysphagia  is
enerally  improved  rapidly  but  long-term  efﬁcacy  is  small
between  6  to  40%  at  1  year)  especially  for  anastomotic
trictures  [59].
A meta-analysis  found  that  clinical  success  (for  dyspha-
ia)  was  about  46.2%  with  a  median  follow  up  of  74  weeks,
nd  was  better  for  plastic  stents  (55%  versus  21%,  P  =  0.02)
ut  only  two  studies  used  metallic  stents  for  caustic  steno-
is  [21].  The  migration  rate  was  about  26.4%,  with  a mean
elay  of  17  days,  and  87%  of  stents  were  removed  between
 to  8  weeks.  The  perforation  rate  was  1.5%  [21].
maging features
DCT  is  usually  performed  using  oral  water.  The  use  of
ral  positive  contrast  material  is  restricted  to  patients
ith  clinical  suspicion  of  esophageal  perforation,  ﬁstula
f  extraluminal  collection  [60].  Usually,  unenhanced  MDCT
xamination  of  the  thorax  and  abdomen  is  performed  ﬁrst
g
a
h
s
igure 2. A 53-year-old woman with unresectable epidermoid carcino
ith endoluminal stent placement and systemic chemotherapy: a: MDC
he stent is correctly placed with satisfactory deployment (arrow); b: M
tent in the esophagus. The stent (arrows) is correctly placed with satisfB.  Malgras  et  al.
o  best  evaluate  stent  position  and  location.  Then  MDCT
s  obtained  with  intravenous  administration  of  iodinated
ontrast  material  and  oral  contrast  (Fig.  2).  The  use  of
utomated  exposure  control  and  iterative  reconstruction  is
ecommended  to  minimize  radiation  dose  [61—64].
Complications  of  esophageal  stenting  can  be  classiﬁed
nto  early  (i.e., occurring  less  than  7  days  following  the
rocedure)  and  late  (i.e.,  occurring  more  than  7  days
fter  the  procedure)  complications  [60].  Complications
nclude  stent  misplacement,  hemorrhage,  perforation,  tra-
heal  compression  [54], stent  migration,  stent  fracturing,
umor  ingrowth  and  tumor  overgrowth,  ﬁstula  formation  and
olus  impaction.
Esophageal  perforation  on  MDCT  manifests  as  peri-
sophageal  gas  bubbles,  mediastinal  ﬂuid  collection  and
xtraluminal  leakage  of  oral  contrast  material  [60,65]. Left
leural  effusion  is  often  present  and  does  not  necessarily
ndicate  esophageal  perforation.
More  rarely,  pneumomediastinum  is  observed.  Pneumo-
ediastinum  indicates  esophageal  perforation.  It  is  more
requently  observed  after  esophageal  balloon  dilation  and
an  be  associated  with  subcutaneous  emphysema  that  is  best
videnced  on  MDCT.
MDCT  helps  detect  esophageal  stent  leak  that  presents  as
resence  of  contrast  material  beyond  the  stent  wall.  Simi-
arly,  MDCT  readily  reveals  stent  fracture  that  often  results
n  buckling  and  incomplete  or  complete  esophageal  obstruc-
ion  [60].  MDCT  reveals  esophageal  perforation  with  distal
ip  of  the  stent  projecting  outside  the  esophageal  lumen.
racheal  compression  by  esophageal  stent  is  evidenced  by
DCT  [54].
Stent  migration  is  best  evidenced  on  MDCT.  In  rare  occa-
ions,  esophageal  stent  may  migrate  into  the  duodenum.
his  is  more  frequent  for  stents  placed  in  the  gastro-
sophageal  junction  [66]. Stent  migration  may  result  in
astrointestinal  perforation  either  at  the  level  of  the  esoph-
gus  or  more  distally  in  the  duodenum  [66]. Valenzuela  et  al.
ave  reported  esophageal  stent  migration  into  the  pleural
pace  [60].
ma of the lower third of the esophagus. The patient was treated
T image in the axial plane shows metallic stent in the esophagus.
DCT image in the coronal; c: in the sagittal plane shows metallic
actory deployment.
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Gastroduodenal stents
Indications
Malignant strictures
SEMS  represent  the  treatment  of  choice  of  gastroduodenal
malignant  strictures  when  curative  surgery  is  not  possi-
ble  (Fig.  3)  [67].  The  most  frequent  indication  for  SEMS
placement  is  duodenal  obstruction  secondary  to  a pan-
creatic  cancer  (up  to  10  to  20%  of  cases),  usually  at  an
advanced  stage  [68—70].  SEMS  are  also  used  in  patients
with  gastroduodenal  obstruction  due  to  surrounding  tumor
[71].  Because  of  rapid  efﬁcacy,  reduced  morbidity  and  low
cost  compared  to  palliative  surgery,  SEMS  are  also  used
as  an  alternative  to  surgery  for  palliation  in  patients  with
poor  life  expectancy  [72,73].  Mehta  et  al.  in  a  prospec-
tive  randomized  trial  found  that  duodenal  stenting  was
superior  to  laparoscopic  gastrojejunostomy  for  malignant
gastric  outﬂow  obstruction  in  terms  of  morbidity,  postop-
erative  pain,  hospital  stay  and  1-month  quality  of  life  [74].
These  results  were  conﬁrmed  in  a  decision  analysis  by  Sid-
diqui  et  al.  who  reported  lower  mortality/morbidity  rates
and  a  cost/beneﬁt  analysis  in  favor  of  duodenal  stents
compared  to  surgery  [75].  Contraindications  for  duodenal
SEMS  include  multiple  stenoses  or  stenosis  that  is  beyond
the  reach  of  the  endoscope  (for  example  in  patients  with
peritoneal  carcinomatosis  or  who  had  previous  surgery),
massive  gastrointestinal  bleeding,  suspicion  of  perforation
and  hemodynamic  instability.
Benign strictures
No  clear  information  is  available  concerning  the  use  of  SEMS
in  benign  gastroduodenal  stenoses,  but  it  may  be  assumed
that  biodegradable  or  extractable  stents  would  represent  a
good  alternative  in  their  management.
ResultsReported  technical  success  rate  is  about  94%  and  the  clinical
success  rate  (deﬁned  by  relief  of  obstructive  symptoms  and
reintroduction  of  oral  feeding)  is  about  84%  [70,76,77].
f
t
w
r
Figure 3. A 56-year-old woman with unresectable gastroduodenal aden
(arrows). The stent is correctly placed with satisfactory deployment (arro
(arrows) deployment; c: 3D reconstruction conﬁrms optimal placement a597
Clinical  success  is  deﬁned  by  relief  of  clinical  symptoms
f  obstruction,  the  reintroduction  of  oral  feeding,  improve-
ent  of  nutritional  status  and  a  better  quality  of  life.
linical  success  of  gastroduodenal  stents  is  between  79  and
1%,  with  fast  recovery  because  60  to  90%  of  patients  are
ble  to  have  oral  solid  food  one  day  after  stent  insertion
70,76].  This  clinical  success  is  prolonged  with  time  since
0  to  100%  of  patients  are  still  able  to  have  oral  feeding  3
nd  6  months  after  stent  insertion,  respectively  [78],  with
 median  stent  patency  of  219  days  [76]. Moreover,  it  is
ossible  to  insert  a second  stent  in  a  ﬁrst  one  in  case  of
rst  stent  obstruction  [76,79].  Predictive  factors  of  stent
atency  are  chemotherapy  and  covered  stent  [80].  Studies
omparing  stenting  with  surgery  for  malignant  stenosis  of
he  gastroduodenal  tract  showed  that  stent  was  associated
ith  a  reduced  time  for  oral  nutrition,  a  reduced  hospital
tay,  a  reduced  cost  but  with  a  short  time  for  recurrent
bstruction  and  second  endoscopic  treatment  [72,81—83].
ndeed  long-term  efﬁcacy  seems  to  be  better  with  surgery,
hich  is  preferred  in  case  of  life  expectancy  of  more  than  2
onths  [83].
In  patients,  with  obstructive  jaundice,  biliary  drainage
an  be  performed  endoscopically  before  duodenal  stent
lacement  [84,85].
omplications
he  morbidity  rate  of  gastroduodenal  stents  is  between
1  and  43%  [78]. Early  complications  include  migration,
bstruction,  biliary  obstruction  (in  case  of  a covered
tent),  perforation,  hemorrhage  (Fig.  4),  and  misplacement
86]. Delayed  complications  include  migration,  perfora-
ion,  obstruction,  duodenal  ﬁstula  or  stent  fracture,  and
an  be  treated  with  a  new  stent.  Migration  rate  for
overed  stent  is  about  25%  [76], and  obstruction  of  non-
overed  stent  is  about  15%  [87]. Risk  factor  for  early
ncovered  stent  obstruction  is  stenosis  of  a  gastrojeju-
al  or  a  gastroduodenal  anastomosis  [88].  Risk  factors
or  perforation  are  previous  dilation,  attempt  to  pass
he  stenosis  with  the  endoscope,  use  of  rigid  guide
ire,  concomitant  corticosteroid  therapy/chemotherapy/
adiotherapy.
ocarcinoma: a: MDCT image in the axial plane shows metallic stent
w); b: MDCT image in the oblique plane conﬁrms satisfactory stent
nd satisfactory deployment.
598  B.  Malgras  et  al.
Figure 4. A 70-year-old woman with unresectable adenocarcinoma of the pancreatic head responsible for major dilatation of the jejunum.
The patient was palliated with non-covered self-expandable metallic stent (Hanarostent): a: MDCT image in the axial plane shows metallic
stent (arrow) in the duodenum. The stent is correctly placed with satisfactory deployment (arrow); b: CT image obtained 17 days after
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btent placement because of hematemesis shows extravasation of io
he hepatic artery indicating arterial injury due to stent placement
maging features
DCT  is  usually  performed  using  oral  water.  The  use  of
ral  positive  contrast  material  is  restricted  to  patients  with
linical  suspicion  of  gastroduodenal  perforation,  ﬁstula  of
xtraluminal  collection  [60].
Duodenal  stent  placement  may  result  in  perforation
hat  manifests  as  retroperitoneal  or  intraperitoneal  free
ir  depending  on  the  site  of  perforation.  Rarely,  per-
oration  may  manifest  with  more  subtle  ﬁndings  and
ree  gas  is  only  observed  adjacent  to  the  distal  tip  of
he  stent.  Extraduodenal  leak  of  contrast  material  is  a
peciﬁc  ﬁnding  for  the  diagnosis  of  duodenal  perfora-
ion.  Similar  to  esophageal  stent,  other  complications
f  duodenal  stents  include  stent  misplacement,  hemor-
hage,  perforation,  stent  migration,  stent  fracturing,  tumor
ngrowth  and  tumor  overgrowth,  ﬁstula  formation  and  bolus
mpaction.
MDCT  helps  detect  duodenal  stent  leak  that  presents
s  presence  of  contrast  material  beyond  the  stent  wall.
imilarly,  MDCT  readily  reveals  stent  fracture  that  often
esults  in  buckling  and  incomplete  or  complete  duodenal
bstruction  [60].  MDCT  reveals  duodenal  perforation  with
istal  tip  of  the  stent  projecting  outside  the  duodenal
umen.  MDCT  is  also  useful  for  elucidating  the  cause  of
uodenal  bleeding  after  duodenal  stent  placement  (Fig.  4)
89].
olonic stents
ntestinal  obstruction  may  be  the  revealing  symptom  of  colo-
ectal  cancer  in  up  to  30%  of  patients.  Previous  studies  have
eported  poor  outcome  and  increased  postoperative  mortal-
ty  for  patients  with  obstructive  colorectal  cancers  [90—92].
mergency  surgery,  though  controversial,  is  an  option  in  this
ituation  but  conveys  high  morbidity  (40  to  60%)  and  mor-
ality  (8  to  20%)  [93,94].  Moreover,  in  case  of  left  colonic
bstruction,  up  to  40—60%  of  patients  will  have  a  permanent
toma  [92].  In  order  to  improve  these  results,  SEMS  have
een  proposed  since  1990s,  ﬁrst  as  a  palliative  treatment
hen  as  a  bridge  to  surgery  [95,96].
S
S
sted contrast material (arrow) originating from the right branch of
ndications
alliative treatment in malignant stenosis
wo  clinical  situations  must  be  distinguished:  ﬁrst  patients
ith  very  poor  life  time  expectancy  whatever  the  cancer
tage  who  will  require  only  comfort  care,  and  patients  with
ate  stage  cancer  who  are  not  eligible  for  surgery  and  who
ill  receive  chemotherapy.  For  patients  with  very  poor  life-
ime  expectancy,  stent  insertion  is  associated  with  a  better
uality  of  life  and  less  unnecessary  surgery.  For  patients  with
onger  lifetime  expectancy  who  will  receive  chemother-
py,  SEMS  can  avoid  stoma,  which  is  generally  permanent,
nd  is  associated  with  lower  morbidity  rate,  shorter  time
o  ﬁrst  chemotherapy,  better  quality  of  life  and  similar
urvival  compared  to  surgery  [97—100].  Two  randomized
ontrolled  trials  reported  lower  stoma  rate,  better  quality
f  life  [101]  and  shorter  hospital  stay  [73]  with  SEMS  com-
ared  to  surgery.  A  third  randomized  controlled  trial  was
erminated  prematurely  because  of  safety  considerations
elated  to  high  colonic  perforation  rate  in  the  SEMS  group
102],  especially  delayed  perforations  in  patients  treated
ith  chemotherapy  and  bevacizumab  [99]. Some  authors
eported  that  adjuvant  bevacizumab  therapy  nearly  tripled
he  risk  of  colonic  perforation  in  case  of  stent  placement
103].  Authors  claimed  that  surgery  was  probably  necessary
fter  SEMS  insertion  in  metastatic  patients  (as  for  bridge  to
urgery)  when  a  prolonged  chemotherapy  is  considered  with
otential  curative  treatment  of  metastases.  Regarding  cost-
eneﬁt  analysis,  SEMS  seems  to  be  better  than  surgery  in
ost  of  the  studies  [97,98,104].  In  conjunction  with  shorter
ospital  stay  and  lower  complications,  cost  reductions  of
0  and  30%  have  been  reported  in  the  palliative  and  bridge
o  surgery  groups,  respectively  [105]. In  case  of  palliative
reatment,  risk  factors  for  complication  after  stent  inser-
ion  include  proximal  location  of  the  stricture  (right  colon),
xtrinsic  lesions,  history  of  radiation  and  chemotherapy  with
evacizumab  [103,106,107].EMS as a ‘‘bridge to surgery’’
EMS  as  a  bridge  to  surgery  is  used  as  a  preoperative  mea-
ure  to  temporarily  relieve  obstruction  before  deﬁnitive
es  
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‘‘elective’’  one-stage  surgical  therapy  8  to  10  days  later  in
patients  with  malignant  stenosis  (Fig.  5).  Several  retrospec-
tive  studies  have  compared  the  combination  of  SEMS  with
surgery  to  surgery  alone  and  found  that  the  combination  of
SEMS  with  surgery  was  associated  with  less  stoma  rate,  less
operative  time,  low  morbidity  rate,  low  intensive  care  stay
and  sometimes  low  early  mortality  rate  than  surgery  alone
[97,98].
One  randomized  controlled  trial  reported  that  SEMS  as
a  bridge  to  surgery  was  associated  with  more  one  step  sur-
geries,  less  permanent  stoma  rate,  low  morbidity  rate  (less
blood  loss,  less  anastomotic  ﬁstulas  or  wound  infection)
[108].  Also,  in  a  meta-analysis,  SEMS  as  a  bridge  to  surgery
was  found  to  have  a  high  successful  primary  anastomosis
and  low  overall  stoma  rates,  with  no  signiﬁcant  differences
in  complications  and  mortality  rates  [93]. This  approach
is  now  validated  in  the  NICE  (National  Institute  for  Clin-
ical  Excellence)  process  [93,109,110].  Moreover,  a  recent
meta-analysis  showed  that  SEMS  as  a  bridge  to  surgery  was
equivalent  to  emergency  surgery  with  respect  to  overall  sur-
vival,  disease-free  survival,  and  recurrence  [111].
To  tone  down  some  encouraging  results,  two  random-
ized  controlled  trials  have  been  terminated  prematurely
because  of  safety  considerations  related  to  colonic  perfo-
rations  and  morbidity  [112,113].  Also,  oncological  safety
of  SEMS  continued  to  remain  uncertain  and  thus  a  mat-
ter  of  concern.  SEMS  is  associated  with  a  high  incidence
of  clinical  and  ‘‘silent’’  perforations,  with  an  estimated
incidence  of  10  to  20%  [114,115].  Clinical  perforation  of
a  tumor  is  considered  as  favoring  factor  for  the  develop-
ment  of  peritoneal  carcinomatosis  after  curative  surgery  for
colon  cancer,  as  is  pointed  out  in  a  recent  and  exhaustive
review  [116].  Another  putative  risk  comes  from  stent  inser-
tion  itself  and  its  subsequent  expansion  within  the  tumor.
The  problems  resulting  from  stent  insertion  include  tumor
perforation,  altered  pathology  and  tumor  cell  dissemination
[114,117].  Indeed  in  a  recent  report,  some  authors  have
shown  a  lower  overall  and  disease-free  survival  associated
with  shorter  recurrence  time  in  the  stent  group  compared
to  surgery  group  [118].  Others  authors  claimed  that  stenting
was  associated  with  higher  local  recurrence  rate  compared
to  emergency  resection  (P  =  0.038).  None  of  these  studies
were  however  randomized  trials  and  therefore  their  results
must  be  taken  with  caution.
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Figure 5. A 61-year-old man with T4 adenocarcinoma of the left colo
axial plane shows metallic stent (arrow) in the left colon. The stent is c
the axial plane after systemic chemotherapy and stent removal shows co599
xternal malignant colonic stenosis
olonic  stenosis  due  to  external  compression  by  an  advanced
ocoregional  tumor  or  a  peritoneal  carcinomatosis  is  usu-
lly  associated  with  failure  of  SEMS  insertion.  Indeed  these
tenoses  are  generally  long  and  multiple  resulting  in  a  high
linical  failure  rate  of  approximately  of  60%  [106]. Only
ransverse  colonic  stenoses  due  to  gastric  cancer  compres-
ion  seems  to  be  associated  with  higher  clinical  success  rates
f  approximately  80%  [119].
enign colonic strictures
se  of  SEMS  in  benign  colonic  obstruction  is  controversial
nd  limited  to  patients  with  tight  strictures  that  recur  after
epeated  dilations  and  in  patients  who  refuse  or  who  are  not
andidate  to  surgery  [120—122]. Only  retrospective  stud-
es  and  case  reports  are  available  concerning  anastomotic
tenoses,  diverticular  stenoses,  radiation-induced  colonic
tenoses  and  Crohn’s  disease  stenoses  [123].  Even  if  the
ate  of  technical  success  ranges  between  90  and  100%,  clin-
cal  success  rate  is  lower  whatever  the  type  of  colonic  stent
uncovered,  fully/partially  covered  stents)  due  to  high  mor-
idity,  with  a  high  rate  of  delayed  complications  [123].
ndeed  stent  migration  is  observed  in  about  40%  of  patients,
specially  in  anastomotic  stenoses  or  when  covered  stents
re  used.  Perforation  rate  in  inﬂammatory  stenosis  is  about
0%,  especially  in  diverticular  diseases.  Also,  clinical  success
s  low  in  radiation-induced  stenosis  because  of  marked  stiff-
ess.  If  several  studies  tend  to  prohibit  the  use  of  SEMS  in
iverticular  or  radiation-induced  stenoses,  its  use  in  ana-
tomotic  stenoses  seems  to  be  promising  especially  with
overed  stents  that  can  be  easily  removed  or  biodegradable
tents.
esults
echnical  success  (deﬁned  as  successful  insertion  of  the
tent  across  the  stricture)  has  been  reported  in  90%  of  cases
79,97,98].  Technical  failure  of  SEMS  placement  is  most  com-
only  due  to  the  inability  to  pass  the  guide  wire  across
he  stricture,  especially  in  cases  with  tortuous  angulated
natomy,  poor  preprocedure  bowel  preparation,  intense
nteral  peristalsis,  or  very  tight  strictures  [98,124,125].
n presenting with acute colonic obstruction: a: MDCT image in the
orrectly placed and allows relief of obstruction; b: MDCT image in
mplete disappearance of tumor (arrow).
6 B.  Malgras  et  al.
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Figure 6. A 66-year-old man who had endoscopic metallic stent
placement for T4 adenocarcinoma of the left colon. MDCT image
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Clinical  success  (deﬁned  by  relief  of  obstructive  symp-
oms  and  adequate  bowel  decompression  within  72  hours)  is
bserved  in  up  to  80%  of  patients  [97,98].
omplications of colonic stenting
olonic  stenting  is  generally  considered  as  a  low  risk  proce-
ure  with  a  mortality  rate  of  approximately  1%  [126,127].
Complications  associated  with  colonic  SEMS  can  be  classi-
ed  as  early  complications,  including  perforation,  bleeding,
nd  misplacement,  and  late  complications  including  mainly
tent  migration,  reobstruction,  and  erosion  or  ﬁstulation  of
he  intestinal  wall  [125,128].  Risk  factors  of  complications
re  male  gender,  stent  diameter  below  or  equal  to  22  mm,
omplete  colonic  obstruction,  operator  experience,  and
tricture  dilation  during  SEMS  insertion  [103].
Self-limited  hemorrhage  occurs  in  0—5%  of  the  cases  and
s  generally  a  minor  complication,  most  likely  related  to
he  tumor  itself  and  does  not  require  a  speciﬁc  treatment
122,125,129].
Colonic  perforation  is  the  most  serious  complication  and
ccurs  in  about  5%  of  procedures  (range:  0—83%)  [98,126]
ith  a  10%  mortality  rate  [126].  In  a  systematic  review,
hot  et  al.  have  reported  3  deaths  in  a  total  of  565  colonic
tent  placements;  two  of  them  were  due  to  colonic  perfo-
ation  [126].  Colonic  perforation  is  predominantly  observed
n  patients  who  had  balloon  dilation  of  the  colonic  steno-
is  or  incomplete  initial  stent  deployment  [126,130,131].
isk  factors  for  early  perforation  following  stent  insertion
re  stenosis  dilation  prior  to  stent  insertion,  try  to  pass  the
tenosis  with  the  endoscope  or  excessive  manipulation  of
uide  wires,  especially  in  the  presence  of  diverticular  dis-
ase  or  early  wall  ischemia  [131].  Type  and  size  of  the  stent
ave  to  ﬁt  stenosis  and  colonic  features  in  order  to  avoid
tent  incarceration.  Late  perforations  are  generally  asso-
iated  with  chemotherapy  and  thus  imply  surgery  3  to  6
onths  after  stent  insertion.
Migration  rate  of  colonic  stents  is  about  11%  (range:  0
o  50%)  [98,104].  Most  of  the  stents  migrate  distally  and
re  automatically  expelled  through  the  anus,  while  symp-
omatic  stents  may  be  removed  endoscopically.  It  can  be
ssociated  with  chemotherapy  due  to  tumor  shrinkage,  or
n  case  of  prior  laser  debulking  or  balloon  before  dilation
nd  lead  to  secondary  obstruction  [125].  Others  factors
hat  predispose  to  stent  migration  include  treatment  of
artial  obstructions  or  extrinsic  compressions,  small  stent
iameter,  colonic  angulation,  insufﬁcient  length  to  allow
tent  ﬂaring,  postoperative  radiotherapy,  and  benign  lesions
122,128,130].  Stent  migration  occurs  also  three  times  more
requently  in  the  distal  rectum  compared  to  the  left  colon
132].  Use  of  non-covered  or  longer/larger  diameter  stents
eems  to  reduce  the  risk  of  migration.
Stent  obstruction  is  most  frequent  in  palliative  stent
atients  and  occur  in  about  10%  of  patients  [127]. Tumor
vergrowth  is  the  most  common  cause  (Fig.  6),  ingrowth
hrough  the  stent  lattice,  mucosal  prolapse,  stent  fracture
nd  fecal  impaction  are  less  frequent  [98,126,131]. In  case
f  stent  obstruction  due  to  cancer  progression,  laser/argon
herapy,  stent  in  stent,  or  surgery  can  be  done  [79,127]. In
ase  of  stool  impaction,  medical  or  endoscopic  desobstruc-
ion  is  mandatory.  This  can  be  precluded  with  low-residue
iet  and  use  of  osmotic  laxative.
h
o
p
mn the axial plane four months after stent placement shows tumor
ngrowth (arrowhead) within stent lumen. The stent (arrow) shows
ormal deployment and no migration.
maging features
hereas  X-ray  imaging  using  barium  enema  has  been  used
n  the  past  to  assess  the  degree  of  luminal  stenosis  and  the
ength  of  the  stenosis,  currently,  MDCT  using  water  enema  is
he  favored  imaging  technique  for  a  comprehensive  evalua-
ion  before  colonic  stent  placement  [133].  One  advantage
f  MDCT  is  that  it  helps  determine  the  cause  of  colonic
bstruction.  In  this  regard,  obstruction  can  be  due  to  intra-
uminal  tumor  process  but  also  to  extraluminal  compression
y  pelvic  neoplasm  or  peritoneal  carcinomatosis.  MDCT  with
ater  enema  is  also  used  to  determine  the  site  of  the
bstruction  and  the  number  of  sites  of  obstruction.  It  is
urrently  acknowledged  that  multiple  sites  of  obstruction
ender  the  patient  unsuitable  for  stent  placement  [131].
In  patients  with  suspected  complications  following
olonic  stenting,  MDCT  is  usually  performed  using  oral  water.
he  use  of  oral  positive  contrast  material  is  restricted  to
atients  with  clinical  suspicion  of  perforation  or  ﬁstula  [60].
Before  stent  placement,  colon  perforation  must  be
xcluded.  This  is  best  depicted  using  MDCT.  After  stent
lacement,  X-ray  pelvic  radiography  is  performed  to  ensure
orrect  placement  and  optimal  expansion.  This  is  also
elpful  for  further  comparison  should  stent  migration  be
uspected  [131]. However,  X-ray  pelvic  radiography  may
how  initially  incomplete  stent  expansion  that  subsequently
ecomes  complete  during  the  following  days.
Following  colonic  stent  placement  in  patients  with
ajor  colonic  dilatation,  MDCT  can  reveal  presence  of
arked  colonic  edema,  which  is  assumed  to  indicate  colonic
schemia  [131].
Colonic  perforation  due  to  stent  placement  is  conﬁrmed
y  MDCT.  MDCT  shows  pneumoperitoneum  and  pericolic  ﬂuid
ccumulation.  Infection  of  pericolic  ﬂuid  collection  can  be
anaged  percutaneously  using  drain  placement.
Finally,  MDCT  is  often  performed  in  patients  whoad  stent  placement  and  symptoms  suggestive  of  colonic
bstruction.  MDCT  can  reveal  reobstruction,  which  is
redominantly  due  to  tumor  overgrowth  although  stent
igration,  tumor  ingrowth  and  fecal  obstruction.
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Conclusion
Currently  stent  insertion  is  well  codiﬁed  regarding  technical,
material  aspects  and  indications.  Except  for  emergencies,
stent  insertion  has  to  be  discussed  during  a  multidisciplinary
cancer  conference  in  order  to  deﬁne  its  use  in  a  multimodal
treatment.  Caution  must  be  taken  concerning  oncologic  out-
comes  of  stent  insertion  in  malignant  strictures.  Also,  benign
strictures  are  more  and  more  treated  with  stents  even  if
low  efﬁcacy  and  high  morbidity  rates  reduce  its  use  in  such
indications.
Take-home  messages
• Self-expandable  metallic  stent  (SEMS)  insertion  is
the  most  common  intervention  for  palliation  of
dysphagia  in  inoperable  patients  with  esophageal
cancer.
• Complications  of  esophageal  stenting  include  stent
misplacement,  hemorrhage,  perforation,  tracheal
compression,  stent  migration,  stent  fracturing,
tumor  ingrowth/overgrowth,  ﬁstula  formation  and
bolus  impaction.
• SEMS  represent  the  treatment  of  choice  of
gastroduodenal  malignant  strictures  when  curative
surgery  is  not  possible.
• Oncological  safety  of  SEMS  continued  to  remain
uncertain  and  thus  a  matter  of  concern.
• Colonic  stenting  is  generally  considered  as  a  low  risk
procedure.
• Benign  strictures  are  more  and  more  treated  with
stents  even  if  low  efﬁcacy  and  high  morbidity  rates
reduce  its  use  in  such  indications.
Clinical caseA  38-year-old  man  with  no  remarkable  prior  history  was
referred  to  the  emergency  department  for  acute  abdominal
pain.  Clinical  examination  revealed  abdominal  tenderness
4
(
t
ﬁ
Figure 7. a: abdominopelvic MDCT image in the axial plane shows st
thickening suggestive for tumor; b: abdominopelvic MDCT image in the 
marked upstream dilatation of the right colon and cecum (arrowhead); c
positive contrast agent shows marked but incomplete stenosis (arrow) of601
nd  symptoms  suggestive  for  colonic  obstruction.  The
atient  did  not  have  fever.
uestions
.  What  is  the  best  imaging  examination  to  conﬁrm  the  diag-
osis?
.  Abdominal  plain  ﬁlm.
.  Abdominal  ultrasonography.
.  MDCT  of  the  abdomen  and  pelvis.
.  Videocolonoscopy.
.  MR  colonography.
.  MDCT  of  the  abdomen  was  performed  ﬁrst  (Fig.  7).
DCT  showed  colon  distention  with  marked  dilatation  of  the
ecum.  Based  on  MDCT  ﬁndings,  what  is  the  most  plausible
ause  of  colonic  obstruction?
.  Acute  episode  of  ulcerative  colitis.
.  Acute  episode  of  Crohn’s  disease.
.  Volvulus  of  the  sigmoid.
.  Colonic  lymphoma.
.  Colonic  adenocarcinoma.
.  After  discussion  between  the  gastroenterologist  and
he  digestive  surgeon,  emergency  colonic  stent  placement
as  considered  because  of  incomplete  tumor  stenosis  and
arked  colon  dilatation.  After  the  procedure,  abdominal
istention  did  not  resolve  and  the  patient  was  still  com-
laining  of  abdominal  pain.  Clinical  examination  revealed
ore  marked  abdominal  distension.  What  is  the  best  imaging
xamination  to  elucidate  the  potential  cause  of  abdominal
ain?
.  Abdominal  plain  ﬁlm.
.  Abdominal  ultrasonography.
.  MDCT  of  the  abdomen  and  pelvis.
.  Videocolonoscopy.
.  MR  colonography..  The  patient  underwent  repeat  MDCT  examination
Figs.  8  and  9).  On  the  basis  of  MDCT  ﬁndings,  what  is
he  most  plausible  scenario  that  may  explain  the  imaging
ndings?
enosis (arrow) of the sigmoid colon with marked circumferential
coronal plane conﬁrms stenosis (arrow) of the sigmoid colon with
: abdominopelvic MDCT image in the axial plane after enema with
 the sigmoid colon with marked circumferential thickening.
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Figure 8. Abdominopelvic MDCT image in the axial plane shows
pneumoperitoneum (arrows).
Figure 9. Abdominopelvic MDCT image in the axial plane shows
p
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Rerforation of the sigmoid colon with misplacement of the metallic
tent (arrows) in the peritoneal cavity.
.  The  patient  had  diastatic  perforation  of  the  cecum.
.  The  patient  had  perforation  of  the  colon  during  stent
placement.
.  The  patient  had  superimposed  volvulus  of  the  sigmoid.
.  The  patient  had  superimposed  volvulus  of  the  cecum.
.  The  patient  had  extraluminal  stent  placement.
nswers
.  C.. E.
. C.
. E.  MDCT  shows  pneumoperitoneum  (arrows  on  Fig.  8)  and
erforation  of  the  colon  with  misplacement  of  the  metallic
tent  (arrows  on  Fig.  9)  in  the  peritoneal  cavity.B.  Malgras  et  al.
nd of the story
urgery  was  performed  immediately  and  consisted  of  proc-
ectomy  with  colorectal  anastomosis  and  temporary  stoma.
istologically,  the  tumor  was  a  T4  tubulated,  moderately
ifferentiated  adenocarcinoma.
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